Evaluation of serum neuropeptide levels in patients with chronic urticaria

Başak, Pınar Yüksel; Erturan, İ̇jlal; Yüksel, Özlem; Kazanoglu, Oya Oylum; Vural, Hüseyín

doi:10.4103/0378-6323.140345

Cited by 14 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…23 To be clinically relevant, substance P in particular should be increased in urticaria. Several studies have shown circulating levels of substance P to be higher in CSU patients compared with healthy individuals [111][112][113] although this was not confirmed by another. 114 Furthermore, measurements of substance P and VIP in the skin showed their concentrations to be higher in urticaria patients than in controls.…”

Section: Is Mast Cell Reactivity Changed?mentioning

confidence: 88%

The role and relevance of mast cells in urticaria

Church

Kolkhir

Metz

et al. 2018

Immunological Reviews

209

198

View full text Add to dashboard Cite

This review presents evidence that the skin mast cell, in particular the MC subtype, is the primary effector cell in urticaria. Mast cells are located in the upper dermis, the ideal situation for wheal formation and sensory nerve stimulation. Increased numbers of mast cells are found in both lesional and non-lesional skin in CSU and inducible urticaria. Mast cell degranulation in the area of wheals has been demonstrated repeatedly by light and electron microscopy. Histamine, PGD and tryptase are found in the venous blood draining wheal formation. The last 2 are specific for mast cells rather than basophils. Mast cell reactivity is increased in active urticaria by local inflammatory cytokines and neuropeptides. Mast cell cytokines and neuropeptides, particularly nerve growth factor, induce a Th2 type inflammation that is particularly obvious at the sites of whealing. In conclusion, autoimmunity, either of Type 1 viz. IgE antibodies to local autoallergens, or Type 2b, viz. IgG autoantibodies to IgE or its receptor, are considered to be the most frequent causes of CSU. In both cases, the mast cell is likely to be the axial cell in producing the wheals.

show abstract

Section: Is Mast Cell Reactivity Changed?mentioning

confidence: 88%

The role and relevance of mast cells in urticaria

Church

Kolkhir

Metz

et al. 2018

Immunological Reviews

209

198

View full text Add to dashboard Cite

show abstract

“…Stress leads to increased levels of neuropeptides such as substance P, which activates mast cells via the MRGPRX2. Stress is a well‐known trigger of CU exacerbations 42‐45 …”

Section: Discussionmentioning

confidence: 99%

The global impact of the COVID‐19 pandemic on the management and course of chronic urticaria

Kocatürk

Salman

Chérrez-Ojeda

et al. 2020

Allergy

View full text Add to dashboard Cite

Introduction The COVID‐19 pandemic dramatically disrupts health care around the globe. The impact of the pandemic on chronic urticaria (CU) and its management are largely unknown. Aim To understand how CU patients are affected by the COVID‐19 pandemic; how specialists alter CU patient management; and the course of CU in patients with COVID‐19. Materials and Methods Our cross‐sectional, international, questionnaire‐based, multicenter UCARE COVID‐CU study assessed the impact of the pandemic on patient consultations, remote treatment, changes in medications, and clinical consequences. Results The COVID‐19 pandemic severely impairs CU patient care, with less than 50% of the weekly numbers of patients treated as compared to before the pandemic. Reduced patient referrals and clinic hours were the major reasons. Almost half of responding UCARE physicians were involved in COVID‐19 patient care, which negatively impacted on the care of urticaria patients. The rate of face‐to‐face consultations decreased by 62%, from 90% to less than half, whereas the rate of remote consultations increased by more than 600%, from one in 10 to more than two thirds. Cyclosporine and systemic corticosteroids, but not antihistamines or omalizumab, are used less during the pandemic. CU does not affect the course of COVID‐19, but COVID‐19 results in CU exacerbation in one of three patients, with higher rates in patients with severe COVID‐19. Conclusions The COVID‐19 pandemic brings major changes and challenges for CU patients and their physicians. The long‐term consequences of these changes, especially the increased use of remote consultations, require careful evaluation.

show abstract

“…138 Patients with CSU exhibit increased wheal reactions to intradermal injections of VIP, 66 as well as moderately, albeit not significantly, increased blood levels of VIP. 107 Blood levels of VIP are also increased in patients with AD, and they correlate with itch intensity in 1 study but not in others. 114,126,127 Similar to SP, responses to VIP skin prick testing and intradermal injections are reduced in patients with AD 81,113,127 (summarized in Table III).…”

Section: The Role Of Mrgprx2 Ligands In Chronic Pruritic Skin Diseasementioning

confidence: 68%

“…Blood levels of SP in patients with CSU were increased in 3 of 4 studies. [105][106][107][108] Also, SP levels were reported to correlate with CSU activity 105 and to be linked to absolute blood basophil counts. 106 SP induced wheal and flare reactions after intradermal injection or skin prick testing.…”

Section: The Role Of Mrgprx2 Ligands In Chronic Pruritic Skin Diseasementioning

confidence: 99%

“…AMP protein levels, but not mRNA, are increased in the lesional skin of patients with AD. 136,[152][153][154][155] Furthermore, the expression of LL-37 and hBD-2 has been reported to moderately correlate with bacterial colony numbers 152 and disease severity in patients with AD quantified with use of the Scoring Atopic [105][106][107] or no difference 108 ; correlation with disease activity 105 [ 114,117,118 ; correlation with intensity of pruritus 114,118 and disease activity 117 [ in patients with cold urticaria, 105 psoriasis, 114 Dermatitis (SCORAD) index. 133,135,153 As a result, LL-37 and hBD-2 have been proposed to serve as biomarkers for AD severity, although AMP expression in the skin of patients with AD does not appear to be linked directly to the degree of skin inflammation as evaluated by dermal infiltrates and epidermal CD3 1 T cells.…”

Section: Activation Of Mrgprx2 By Eosinophil Granule Proteinsmentioning

confidence: 99%

See 1 more Smart Citation